Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. For more, please visit: bicara.com.

Biocon

Omega Funds

RA Capital Management

Bioqube Ventures

Invus

Janus Henderson Investors

Aisling Capital

Piper Heartland Healthcare Capital

PremjiInvest

Braidwell

Deerfield Management

Eight Roads Ventures

F-Prime Capital

Fairmont Capital

The Rise Fund

Bicara Therapeutics

COM:BICARA